Compound Formulation Active Pharmaceutical Ingredients and the Associated Adverse Effects and Potential Contraindications/Warnings and Precautions

Bimatoprost + Dorzolamide + Timolol

Bimatoprost

Possible Adverse Reaction	Potential Contraindications / Warnings and Precautions
Conjuctival hyperemia and edema, conjunctival hemorrhage, eye irritation, eye pain, eye pruritus, erythema of eyelid, eyelids pruritus, growth of eyelashes, hypertrichosis, instillation site irritation, punctate keratitis, skin hyperpigmentation, vision blurred, and visual acuity reduced. Iris pigmentation changes (brown), Eyelid skin darkening, Eyelash changes (increased length, thickness, pigmentation and number of lashes). When Bimatoprost is discontinued increased pigmentation of the iris is likely to be permanent, while pigmentation of the periobital tissue and eyelash changes have been reported to be reversible. Intraocular inflammation, Macular edema, Foreign body sensation, Punctate keratitis, Stinging, Blurred vision, Itching, Burning, Excessive tearing, Eyelid discomfort/pain, Dry eye, Eye pain, Eyelid margin crusting, Erythema of the eye lid, Photophobia, Asthma like symptoms, Dyspnea. Bacterial keratitis possible with multiple use container.	Patients less than 16 years, Lactation, Pregnancy, Child-bearing aged females. Potential for cross-sensitivity to any components. Caution in patients with active intraocular inflammation (trauma or infection), uveitis, aphakic patients, pseudophakic patients with torn posterior lens capsule, known risk factors for macular edema.

Dorzolamide

Possible Adverse Reaction	Potential Contraindications / Warnings and Precautions
Ocular burning, stinging, or discomfort, immediately following ocular administration. Bitter taste, Superficial punctate keratitis, Ocular allergic reaction, Conjunctivitis and lid reactions, Blurred vision, Eye redness, Tearing, Dryness, Photophobia, Headache, Nausea, Asthenia/fatigue, and rarely Skin rashes, Urolithiasis, Iridocyclitis. Stevens-Johnson syndrome, dizziness, parasthesia, ocular pain, transient myopia, choroidal detachment following filtration surgery, eyelid crusting; dyspnea, epistaxis, dry mouth and throat irritations. Bacterial keratitis associated with the use of multiple-dose containers.	Neonates and Patients Less than 12 Years, Lactation, Pregnancy. Sulfonamide allergy or Hypersensitivity to any of the components. Patients with low endothelial cell counts, acute anglepclosure glaucoma. Concomitant use with oral carbonic anhydrase inhibitors, high-dose salicylate therapy, severe renal impairment.

Timolol Maleate

Possible Adverse Reaction	Potential Contraindications / Warnings and Precautions
Ocular burning/stinging on instillation, blurred vision, cataract, conjunctival injection, headache, hypertension, Infection, Itching, and decreased visual acuity, potentiation of respiratory reactions including asthma, asthenia/fatigue and chest pain, bradycardia, arrhythmia, hypotension, syncope heart block, cardiac arrest, pulmonary edema, raynaud's phenomenon, nausea, diarrhea, dyspepsia, anorexia, dry mouth, dizziness, somnolence, insomnia, depression, confusion, alopecia, bronchospasm, anaphylaxis, nasal congestion, potentiation of muscle weakness, masked hypoglycemia, masked thyrotoxicosis, ocular pain, ocular irritation (conjuctivitis, blepharitis, keratitis, ocular pain, discharge, crusting, foreign body sensation, tearing, dry eyes, ptosis), visual disturbances, and decreased libido, choroidal detachment after filtration procedures. Bacterial keratitis associated with the use of multiple-dose containers.	Patients Less than 12 Years, Lactation, Pregnancy, Bronchial Asthma, Severe COPD, chronic bronchitis, emphysema, brochospastic disease, History of Sinus Bradycardia, Second or third-degree atrioventricular block, Overt cardiac failure, Cardiogenic shock. Known hypersensitivity to any components. Do not use concomitantly with systemic beta-blockers, calcium antagonists, catecholamine-depleting drugs, digitalis, quinidine. Do not use in angle-closure glaucoma.

*For professional use only. OSRX specializes in customizing compounded medications to meet unique patient needs. Compounded drugs are not FDA-approved, which means they have not undergone FDA premarket review for safety, effectiveness, and quality. **View potential adverse events and contraindications at: www.osrxpharmaceuticals.com/osrx-api-aecontraindication**

1120 Kensington Ave., Suite E, Missoula, MT 59801 | P: 855.466.1076 | F1: 406.541.6267 | F2: 866.515.0196 | osrxpharmaceuticals.com